{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:01:51Z","timestamp":1789012911572,"version":"build-2803163510"},"reference-count":47,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B-cell lymphoma 2 (BCL-2) has recently emerged as a therapeutic target for early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL), a high-risk subtype of human T-cell ALL. The major clinical challenge with targeted therapeutics, such as the BCL-2 inhibitor ABT-199, is the development of acquired resistance. We assessed the in vivo response of luciferase-positive LOUCY cells to ABT-199 monotherapy and observed specific residual disease in the splenic microenvironment. Of note, these results were confirmed by using a primary ETP-ALL patient-derived xenograft. Splenomegaly has previously been associated with poor prognosis in diverse types of leukemia. However, the exact mechanism by which the splenic microenvironment alters responses to specific targeted therapies remains largely unexplored. We show that residual LOUCY cells isolated from the spleen microenvironment displayed reduced BCL-2 dependence, which was accompanied by decreased BCL-2 expression levels. Notably, this phenotype of reduced BCL-2 dependence could be recapitulated by using human splenic fibroblast coculture experiments and was confirmed in an in vitro chronic ABT-199 resistance model of LOUCY. Finally, single-cell RNA-sequencing was used to show that ABT-199 triggers transcriptional changes in T-cell differentiation genes in leukemic cells obtained from the spleen microenvironment. Of note, increased expression of CD1a and sCD3 was also observed in ABT199-resistant LOUCY clones, further reinforcing the idea that a more differentiated leukemic population might display decreased sensitivity toward BCL-2 inhibition. Overall, our data reveal the spleen as a site of residual disease for ABT-199 treatment in ETP-ALL and provide evidence for plasticity in T-cell differentiation as a mechanism of therapy resistance.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004177","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T22:52:56Z","timestamp":1617922376000},"page":"1963-1976","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7550-1289","authenticated-orcid":false,"given":"Alessandra","family":"Di Grande","sequence":"first","affiliation":[{"name":"Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Peirs","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Medicine and"},{"name":"Cancer Research Institute Ghent, Ghent University, Ghent, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-8961","authenticated-orcid":false,"given":"Paul D.","family":"Donovan","sequence":"additional","affiliation":[{"name":"Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland;"},{"name":"Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Van Trimpont","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Medicine and"},{"name":"Cancer Research Institute Ghent, Ghent University, Ghent, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Morscio","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Medicine and"},{"name":"Cancer Research Institute Ghent, Ghent University, Ghent, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Lintermans","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Medicine and"},{"name":"Cancer Research Institute Ghent, Ghent University, Ghent, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy","family":"Reunes","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vandamme","sequence":"additional","affiliation":[{"name":"Cancer Research Institute Ghent, Ghent University, Ghent, Belgium;"},{"name":"Data Mining and Modelling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-8570","authenticated-orcid":false,"given":"Steven","family":"Goossens","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Medicine and"},{"name":"Cancer Research Institute Ghent, Ghent University, Ghent, Belgium;"},{"name":"Department of Diagnostic Sciences, Ghent University, Ghent, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Lavie","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL;"},{"name":"The Jesse Brown VA Medical Center, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lock","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Institute, School of Women\u2019s and Children\u2019s Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-7794","authenticated-orcid":false,"given":"Jochen H. M.","family":"Prehn","sequence":"additional","affiliation":[{"name":"Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland;"},{"name":"Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-7205","authenticated-orcid":false,"given":"Pieter","family":"Van Vlierberghe","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Medicine and"},{"name":"Cancer Research Institute Ghent, Ghent University, Ghent, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-4031","authenticated-orcid":false,"given":"Triona","family":"N\u00ed Chonghaile","sequence":"additional","affiliation":[{"name":"Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland;"},{"name":"Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"issue":"7","key":"2021040815320412200_B1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2021040815320412200_B2","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/blood-2012-12-475483","article-title":"Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy","volume":"121","author":"Boyerinas","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2021040815320412200_B3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbamcr.2015.08.015","article-title":"Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting","volume":"1863","author":"Chiarini","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2021040815320412200_B4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"2021040815320412200_B5","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a Group for Research on Adult Acute Lymphoblastic Leukemia Study","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"2021040815320412200_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"key":"2021040815320412200_B7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/asheducation-2014.1.190","article-title":"Balancing cure and long-term risks in acute lymphoblastic leukemia","volume":"2014","author":"Silverman","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"2021040815320412200_B8","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2007.12.2820","article-title":"Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study","volume":"26","author":"Oudot","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021040815320412200_B9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"25","key":"2021040815320412200_B10","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2021040815320412200_B11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/leu.2013.377","article-title":"BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines","volume":"28","author":"Anderson","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2021040815320412200_B12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2021040815320412200_B13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2021040815320412200_B14","doi-asserted-by":"crossref","first-page":"11171","DOI":"10.1038\/ncomms11171","article-title":"GATA3 induces human T-cell commitment by restraining Notch activity and repressing NK-cell fate","volume":"7","author":"Van de Walle","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"2021040815320412200_B15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2021040815320412200_B16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2021040815320412200_B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00127","article-title":"First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia","volume":"2","author":"Numan","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"2021040815320412200_B18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"7","key":"2021040815320412200_B19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"issue":"7","key":"2021040815320412200_B20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"2021040815320412200_B21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","article-title":"High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia","volume":"114","author":"Gutierrez","year":"2009","journal-title":"Blood"},{"key":"2021040815320412200_B22","author":"PedcBioPortal for Integrated Childhood Cancer Genomics"},{"issue":"1","key":"2021040815320412200_B23","doi-asserted-by":"crossref","first-page":"17049","DOI":"10.1038\/cddiscovery.2017.49","article-title":"Tumor cell senescence response produces aggressive variants","volume":"3","author":"Yang","year":"2017","journal-title":"Cell Death Discov"},{"issue":"3","key":"2021040815320412200_B24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL","volume":"19","author":"Tzoneva","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"2021040815320412200_B25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ng.2508","article-title":"Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia","volume":"45","author":"De Keersmaecker","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"2021040815320412200_B26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/jcp.53.12.940","article-title":"Chronic myeloid leukaemia occurring in a patient with hairy cell leukaemia","volume":"53","author":"Wandroo","year":"2000","journal-title":"J Clin Pathol"},{"issue":"9","key":"2021040815320412200_B27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1101\/gad.13.9.1073","article-title":"c-Myb is essential for early T cell development","volume":"13","author":"Allen","year":"1999","journal-title":"Genes Dev"},{"issue":"8","key":"2021040815320412200_B28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"12","key":"2021040815320412200_B29","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.3324\/haematol.2018.190587","article-title":"A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing","volume":"103","author":"Verboom","year":"2018","journal-title":"Haematologica"},{"key":"2021040815320412200_B30","doi-asserted-by":"crossref","unstructured":"Lavaert M , et al. Single cell profiling of immature human postnatal thymocytes resolves the complexity of intra-thymic lineage differentiation and thymus seeding precursors. bioRxiv, 2020:2020.04.07.007237.","DOI":"10.1101\/2020.04.07.007237"},{"key":"2021040815320412200_B31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/0008-5472.CAN-17-2106","article-title":"A novel l-asparaginase with low l-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo","volume":"78","author":"Nguyen","year":"2018","journal-title":"Cancer Res"},{"issue":"18","key":"2021040815320412200_B32","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2021040815320412200_B33","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2021040815320412200_B34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando","year":"2002","journal-title":"Cancer Cell"},{"issue":"1","key":"2021040815320412200_B35","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.V75.1.166.166","article-title":"Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study","volume":"75","author":"Shuster","year":"1990","journal-title":"Blood"},{"issue":"6","key":"2021040815320412200_B36","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.2820360926","article-title":"Initial features and prognosis in 363 children with acute lymphocytic leukemia","volume":"36","author":"Simone","year":"1975","journal-title":"Cancer"},{"issue":"1-2","key":"2021040815320412200_B37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/10428199209053612","article-title":"Role of splenectomy in chronic lymphocytic leukaemia with massive splenomegaly and cytopenia","volume":"7","author":"Majumdar","year":"1992","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2021040815320412200_B38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1148\/radiology.154.3.3969481","article-title":"The spleen in Hodgkin disease: diagnostic value of CT","volume":"154","author":"Strijk","year":"1985","journal-title":"Radiology"},{"issue":"22","key":"2021040815320412200_B39","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMicm1013222","article-title":"Images in clinical medicine. Massive splenomegaly in hairy-cell leukemia","volume":"367","author":"Monterroso","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"2021040815320412200_B40","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood-2004-08-3210","article-title":"The splenic microenvironment is a source of proangiogenesis\/inflammatory mediators accelerating the expansion of murine erythroleukemic cells","volume":"105","author":"Shaked","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2021040815320412200_B41","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1097-0142(19860201)57:3<644::AID-CNCR2820570341>3.0.CO;2-O","article-title":"Splenectomy for hairy cell leukemia. A clinical review of 63 patients","volume":"57","author":"Van Norman","year":"1986","journal-title":"Cancer"},{"issue":"4","key":"2021040815320412200_B42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"2021040815320412200_B43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri2476","article-title":"GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation","volume":"9","author":"Ho","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2021040815320412200_B44","first-page":"954275","article-title":"Spleen as a site for hematopoiesis of a distinct antigen presenting cell type","volume":"2011","author":"O\u2019Neill","year":"2011","journal-title":"Stem Cells Int"},{"issue":"10","key":"2021040815320412200_B45","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/j.clml.2018.07.289","article-title":"Feasibility of the combination of venetoclax and asparaginase-based chemotherapy for adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"18","author":"El-Cheikh","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2021040815320412200_B46","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"11","key":"2021040815320412200_B47","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/1963\/1804921\/advancesadv2021004177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/1963\/1804921\/advancesadv2021004177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T22:47:22Z","timestamp":1724798842000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/7\/1963\/475682\/The-spleen-as-a-sanctuary-site-for-residual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004177","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]}}}